Investigation of Immunovant, Inc.

Immunovant, Inc. (IMVT) Misled Shareholders About the Viability of its Drug Candidate IMVT-1401

On September 29, 2019, Health Sciences Acquisitions Corporation (HSAC), then a special purpose acquisition company, entered into an agreement with Immunovant Sciences Ltd., a private biopharmaceutical company, to effect a merger between the two entities.  As a result of the merger, HSAC acquired all shares of Immunovant Sciences and Immonvant Sciences became a wholly owned subsidiary of HSAC.  HSAC then changed its name to Immunovant, Inc.

During the relevant period, defendants made false and/or misleading statements and/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Immunovant Sciences prior to the merger; (ii) HSAC ignored safety issues associated with Immunovant Science’s drug candidate IMVT-1401; and (iii) IMVT-1401 was less safe than the Company had led investors to believe, which foreseeably diminished its prospects for regulatory approval, commercial viability and profitability.

On February 2, 201, Immunovant issued a press release announcing “a voluntary pause of dosing in its original clinical trials for IMVT-1401,” and disclosed that it “has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low density lipoproteins] levels in IMVT-1401-treated patients.”  On this news, Immunovant’s stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021.

If you purchased shares of Immunovant, Inc. (IMVT) between October 2, 2019 and February 1, 2021, you have until April 20, 2021, to ask the court to appoint you lead plaintiff for the class.  

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started

Name*
Ticker + Amount
This field is for validation purposes and should be left unchanged.